Pre-Open Stock Movers 06/26: (MDCA) (VXRT) (GPS) Higher; (SHIP) (SOLY) (NKE) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Argus Reiterates Buy Rating on Nike (NKE) Following 4Q
June 30, 2020 7:26 AM EDTArgus analyst John Staszak reiterated a Buy rating and $115.00 price target on Nike (NYSE: NKE) following the company's 4Q earnings report. Nike reported fiscal 4Q20 revenue and EPS that missed estimates. Revenue of $6.3 billion. the consensus estimate had called for revenue of $7.3 billion. The adjusted... More
Altimmune (ALT) Reports First Patient Dosing in Phase 1b Clinical Trial of NasoShield
June 30, 2020 7:04 AM EDTAltimmune, Inc. (NASDAQ: ALT) today announced dosing of the first patient in the Companys Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. The NasoShield program is being developed under a contract with the Biomedical Advanced Research and Development Authority (BARDA), with a total potential value of $133.7 million if all options in the contract (HHSO100201600008C) are exercised.
NasoShield is the only single dose anthrax vaccine in development that is supported by BARDA, and has the potential to provide a significant improvement over the available two- and... More
